VNDA Valuation

Vanda Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

4.750

+0.24(5.322%)1D

Overview
Forecast
Valuation
Earnings

VNDA Relative Valuation

VNDA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VNDA is overvalued; if below, it's undervalued.

Historical Valuation

Vanda Pharmaceuticals Inc (VNDA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.01 is considered Undervalued compared with the five-year average of -17.17. The fair price of Vanda Pharmaceuticals Inc (VNDA) is between 6.48 to 12.46 according to relative valuation methord. Compared to the current price of 4.68 USD , Vanda Pharmaceuticals Inc is Undervalued By 27.74%.

Relative Value

Fair Zone

6.48-12.46

Current Price：4.68

27.74%

Undervalued

-3.49

Trailing

Forward

0.00

EV/EBITDA

Vanda Pharmaceuticals Inc. (VNDA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 4.81. The thresholds are as follows: Strongly Undervalued below -8.57, Undervalued between -8.57 and -1.88, Fairly Valued between 11.51 and -1.88, Overvalued between 11.51 and 18.20, and Strongly Overvalued above 18.20. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.35

EV/EBIT

Vanda Pharmaceuticals Inc. (VNDA) has a current EV/EBIT of 0.35. The 5-year average EV/EBIT is 12.73. The thresholds are as follows: Strongly Undervalued below -23.38, Undervalued between -23.38 and -5.33, Fairly Valued between 30.78 and -5.33, Overvalued between 30.78 and 48.83, and Strongly Overvalued above 48.83. The current Forward EV/EBIT of 0.35 falls within the Historic Trend Line -Fairly Valued range.

1.03

Vanda Pharmaceuticals Inc. (VNDA) has a current PS of 1.03. The 5-year average PS is 2.04. The thresholds are as follows: Strongly Undervalued below 0.42, Undervalued between 0.42 and 1.23, Fairly Valued between 2.85 and 1.23, Overvalued between 2.85 and 3.66, and Strongly Overvalued above 3.66. The current Forward PS of 1.03 falls within the Undervalued range.

0.00

P/OCF

Vanda Pharmaceuticals Inc. (VNDA) has a current P/OCF of 0.00. The 5-year average P/OCF is 21.13. The thresholds are as follows: Strongly Undervalued below -162.20, Undervalued between -162.20 and -70.53, Fairly Valued between 112.80 and -70.53, Overvalued between 112.80 and 204.46, and Strongly Overvalued above 204.46. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Vanda Pharmaceuticals Inc. (VNDA) has a current P/FCF of 0.00. The 5-year average P/FCF is 1.77. The thresholds are as follows: Strongly Undervalued below -9.87, Undervalued between -9.87 and -4.05, Fairly Valued between 7.59 and -4.05, Overvalued between 7.59 and 13.41, and Strongly Overvalued above 13.41. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Vanda Pharmaceuticals Inc (VNDA) has a current Price-to-Book (P/B) ratio of 0.56. Compared to its 3-year average P/B ratio of 0.62 , the current P/B ratio is approximately -9.60% higher. Relative to its 5-year average P/B ratio of 1.05, the current P/B ratio is about -46.59% higher. Vanda Pharmaceuticals Inc (VNDA) has a Forward Free Cash Flow (FCF) yield of approximately -24.62%. Compared to its 3-year average FCF yield of -12.26%, the current FCF yield is approximately 100.76% lower. Relative to its 5-year average FCF yield of -4.49% , the current FCF yield is about 447.92% lower.

0.55

P/B

Median3y

0.62

Median5y

1.05

-24.25

FCF Yield

Median3y

-12.26

Median5y

-4.49

Competitors Valuation Multiple

The average P/S ratio for VNDA's competitors is 1.82, providing a benchmark for relative valuation. Vanda Pharmaceuticals Inc Corp (VNDA) exhibits a P/S ratio of 1.03, which is -43.42% above the industry average. Given its robust revenue growth of 4.19%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

VNDA.O

Vanda Pharmaceuticals Inc

Neumora Therapeutics Inc

scPharmaceuticals Inc

Lifecore Biomedical Inc

2.03

-3.81%

281.40M

Performance Decomposition

Market capitalization of VNDA decreased by 10.21% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -8.95 to -51.73.

The secondary factor is the Revenue Growth, contributed 4.19%to the performance.

Overall, the performance of VNDA in the past 1 year is driven by Margin Expansion. Which is more sustainable.

4.19%

50.47M → 52.59M

Revenue Growth

477.99%

-8.95 → -51.73

Margin Expansion

-492.39%

1.01 → -3.94

P/E Change

-10.21%